On November 18 2025, Wearable Devices Ltd. showcased a pre‑commercial electromyography‑driven weight‑estimation capability on its Mudra Link neural wristband. The demo translates surface EMG signals into quantitative estimates of weight, torque, and applied force during lifting actions, leveraging the company’s newly granted U.S. patent “Gesture and Voice‑Controlled Interface Device.” This milestone expands the Mudra platform’s functionality beyond gesture control, positioning the company to enter industrial, sports, healthcare, and XR markets that demand precise force measurement.
The patent, granted in May 2025, outlines a method for mapping EMG waveforms to physical effort metrics, enabling the wristband to infer load without external sensors. By embedding this capability, Wearable Devices can offer physics‑aware, touchless interaction across consumer and enterprise products, a core part of its long‑term vision.
The demonstration signals a strategic pivot toward monetizing the Mudra platform in high‑margin verticals. Management noted that the technology could unlock new revenue streams in robotics, industrial automation, and medical rehabilitation, where accurate force feedback is critical. However, the feature remains pre‑commercial; the company has not yet validated accuracy in diverse real‑world conditions or scaled production.
In the first half of 2025, Wearable Devices reported revenue of $294,000, down 25% from $394,000 in H1 2024, while net loss narrowed to $3.7 million from $4.2 million. Full‑year 2024 revenue rose to $522,000 from $82,000 in 2023, but net loss increased to $7.9 million. These figures illustrate ongoing financial challenges despite the technology’s promise. The company’s recent $3.3 million equity offering in October 2025 reflects a need to shore up capital for R&D and commercialization.
Following the announcement, the company’s shares surged roughly 10% in pre‑market trading, reflecting investor enthusiasm for the patent‑backed innovation. Analysts highlighted the potential for the weight‑estimation feature to differentiate Wearable Devices in a crowded wearable market, though they cautioned that the pre‑commercial status and financial volatility could temper long‑term upside.
Management emphasized continued investment in R&D to refine the EMG algorithms and expand the product roadmap. While the company remains focused on achieving commercial viability, it also plans to pursue strategic partnerships with industrial and healthcare firms to accelerate market entry. The next milestone will be a field‑test rollout and a commercial launch timeline, which management expects within 12–18 months.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.